Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Nurix Therapeutics (NRIX) over the last 6 years, with Q4 2025 value amounting to $1.9 million.

  • Nurix Therapeutics' Amortizatization of Intangibles fell 4655.02% to $1.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $10.3 million, marking a year-over-year decrease of 855.78%. This contributed to the annual value of $10.3 million for FY2025, which is 855.78% down from last year.
  • Nurix Therapeutics' Amortizatization of Intangibles amounted to $1.9 million in Q4 2025, which was down 4655.02% from $2.2 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Amortizatization of Intangibles high stood at $3.7 million for Q3 2024, and its period low was $742000.0 during Q1 2021.
  • Its 5-year average for Amortizatization of Intangibles is $1.8 million, with a median of $1.4 million in 2023.
  • As far as peak fluctuations go, Nurix Therapeutics' Amortizatization of Intangibles skyrocketed by 937500.0% in 2021, and later plummeted by 4655.02% in 2025.
  • Nurix Therapeutics' Amortizatization of Intangibles (Quarter) stood at $853000.0 in 2021, then surged by 66.24% to $1.4 million in 2022, then increased by 28.56% to $1.8 million in 2023, then surged by 91.61% to $3.5 million in 2024, then plummeted by 46.55% to $1.9 million in 2025.
  • Its Amortizatization of Intangibles stands at $1.9 million for Q4 2025, versus $2.2 million for Q3 2025 and $2.7 million for Q2 2025.